Alpha Tau Medical Ltd.
NASDAQ:DRTS · NASDAQ Capital Market
+$0.04 today
Vol 0.57M · Avg 0.69M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-55.3%
avg 628.1%
ROIC
-43.5%
avg -23.2%
ROA
-40.0%
avg -34.3%
Analysis
ROA is currently the strongest return metric at -40.0% versus its period average of -34.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Uzi Sofer | Chief Executive Officer & Chairman | $1.26M | — | 56 | $1.25M | 1.38% |
Raphi Levy | Chief Financial Officer | $763,000.00 | — | 41 | $162,680.00 | 0.18% |
Robert Den | Chief Medical Officer & Member of Scientific Advisory Board | $756,000.00 | — | 47 | — | — |
Ronen Segal | Chief Technology Officer | $435,000.00 | — | 53 | — | — |
Amnon Gat | Chief Operations Officer | $251,000.00 | — | 51 | — | — |
Yael Zeiger | Corporate Controller | — | — | 43 | — | — |
Yona Keisari | Chief Scientific Officer & Member of Scientific Advisory board | — | — | 79 | — | — |
Rebecca Becker | Vice President of legal | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$352,115.25
Net Sentiment
$352,115.25
Net selling
Most Active
Levy Raphi
2 transactions
| Date | Insider | Type | Shares | Price | Value | |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Levy Raphi Direct | Sell | 15.0K | $10.76 | $161,356.50 | |
| Jun 3, 2026 | Levy Raphi Direct | Sell | 17.5K | $10.90 | $190,758.75 |
Analysis
Insiders reported 0 buys worth $0.00 and 2 sells worth $352,115.25 over the last 12 months. That adds up to net selling of $352,115.25. Levy Raphi was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Alto Neuroscience, Inc.
NYSE:ANRO
$773.12M
Candel Therapeutics, Inc.
NASDAQ:CADL
$438.11M
DBV Technologies S.A.
NASDAQ:DBVT
$383.59M
Amarin Corporation plc
NASDAQ:AMRN
$333.61M
Cellectis S.A.
NASDAQ:CLLS
$311.80M
DiaMedica Therapeutics Inc.
NASDAQ:DMAC
$305.79M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$300.81M
AC Immune S.A.
NASDAQ:ACIU
$240.19M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$116.72M
Genelux Corporation
NASDAQ:GNLX
$107.96M
Who manages DRTS?
Alpha Tau Medical Ltd. (DRTS) lists 8 active executives. The top listed executive is Yael Zeiger, Corporate Controller.
Are DRTS insiders buying or selling?
Recent insider activity shows net selling of $352,115.25.
Explore More
Continue the stock analysis
Jump to another research area for this company.